![Ben Harshbarger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ben Harshbarger
General Counsel bei
XILIO THERAPEUTICS, INC.
Profil
Benjamin J.
Harshbarger is Chief Legal Officer at Xilio Therapeutics, Inc. since 2026.
Formerly, Mr. Harshbarger was Chief Legal Officer at Astria Therapeutics, Inc. from 2021 to 2026, Chief Executive Officer & General Counsel at Novelion Therapeutics, Inc. from 2018 to 2019, General Counsel at Aegerion Pharmaceuticals, Inc. from 2015 to 2016, Senior Director-Corporate Counsel at Cubist Pharmaceuticals LLC from 2008 to 2012, Senior Director-Deputy General Counsel at ViaCell, Inc. from 2006 to 2008, Associate General Counsel at Biogen, Inc. from 2001 to 2006, Associate at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC from 1996 to 2001.
Education includes undergraduate studies at the University of Richmond and graduate studies at Boston College Law School.
Aktive Positionen von Ben Harshbarger
| Unternehmen | Position | Beginn |
|---|---|---|
| XILIO THERAPEUTICS, INC. | General Counsel | 29.06.2026 |
Ehemalige bekannte Positionen von Ben Harshbarger
| Unternehmen | Position | Ende |
|---|---|---|
| ASTRIA THERAPEUTICS, INC. | General Counsel | 23.01.2026 |
| NOVELION THERAPEUTICS INC. | Vorstandsvorsitzender | 31.12.2019 |
| AEGERION PHARMACEUTICALS, INC. | General Counsel | 01.07.2016 |
| CUBIST PHARMACEUTICALS INC | General Counsel | 01.03.2012 |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology Provides and develops cellular medicine for the treatment of diseases | Corporate Officer/Principal | 01.03.2008 |
Ausbildung von Ben Harshbarger
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology Provides and develops cellular medicine for the treatment of diseases | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Astria Therapeutics, Inc.
 Astria Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel therapeutics for rare and niche allergic & immunological diseases | Health Technology |
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
 Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
University of Richmond
 University of Richmond Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boston College Law School
 Boston College Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Wählen Sie MarketScreener 
